| Cancer Site | Case/control | Population | Country | OR/HR (95% CI) | value | Ref. |
| Breast | (459) 25,571/(179) 30,056 | (Meta-analysis) | | 3.01 (2.53–3.58) | | [32] |
| Breast | 1,828/7,030 | (Cases/controls) | UK, FI, NE, GE, RU | 6.43 (4.33–9.56) | <0.0001 | [33] |
| Breast | (120) 2,554/(37) 3,267 | (Familial cases) | NE | 4.30 (2.97–6.25) | <0.0001 | [34] |
| Breast | 3,882/8,609 | (Cases/controls) | CA | 2.6 (1.1–5.8) | 0.05 | [35] |
| Breast | 75/300 | (Cases/controls) | SW | 2.5 | 0.26 | [36] |
| Breast | 708 bilateral + 1,395 unilateral | (Cases only) | US, DE | 1.8 (0.6–5.4) | | [37] |
| Breast | 71/1,692 | (Cases/controls) | NE | 4.1 (1.2–14.3) | 0.05 | [38] |
| Breast |
(0) 668 | (Cases only) | MAL | | | [39] |
| Breast | 1,101/4,665 | (Cases/controls) | DE | 1.2 (0.7–2.1) | | [24] | | (Breast) | | 3.2 (1.0–9.9) | | | | (Colorectal) | | 1.6 (0.4–6.5) | | |
| Breast | 161/153 | | US | NS | | [40] |
| Breast | 2,311/496 | (Female cases/controls) | CA | 6.65 (2.37–18.68) | | [41] | | | US | 0.12 (0.02–0.89) | | |
| Breast | 1,071/1,620 | | UK, NE, CA, US, GE | 1.1% of controls versus 5.1% of cases | 0.00000003 | [42] |
| Breast | 300/1,665 | | US | 1% among cases versus 0.3% of controls | 0.1 | [43] |
| Breast | 10,860/9,065 | (Aggregate) | UK, NE, FI, GE, AU | 2.34 (1.72–3.20) | 0.0000001 | [44] |
| Breast | (0) 493 | (Cases only) | KO | | | [45] |
| Breast | 903/1,016 | | IR | 0.5% of cases versus 0.1% of controls; 5.65 (0.66–48.46) | 0.09 | [46] |
| Breast | 1,479 | (Cases only) | US | 2.1 (1.0–4.3) | 0.049 | [47] |
| Breast | 1,035/1,885 | (Positive family history) | FI | 2.27 (1.11–4.63) | 0.021 | [48] | | (Bilateral) | | 6 (1.87–20.32) | 0.007 | |
| Breast | 300 | (Cases only) | AU | 0.6% of cases | | [49] |
| Breast | 237/331 | (Cases/controls) | NE | 11.4% of cases versus 2.8% of controls | 0.001 | [50] |
| Breast | 302 | (Cases only) | RU | 3% of cases. | | [51] |
| Breast | (0) 400/(0) 400 | | SP | | | [52] |
| Breast | (0) 196/(0) 1,024 | | CHL | | | [53] |
| Breast | (0) 102 | (Familial cases) | US | | | [54] |
| Breast | 507/513 | (Cases/controls) | FR | 1.14% in cases versus 0.29% in controls; 5.18 | 0.004 | [55] |
| Breast | 5,953 | (Cases only) | PL | 3.6 (2.1–6.2) | 0.0001 | [56] | | (Prostate) | | 4.4 (2.2–8.7) | 0.0001 | | | (Colon) | | 4.2 (2.4–7.8) | 0.0001 | |
| Breast | 8,612 | (Cases only) | UK | | | [57] |
| Breast, Colorectal | 75 | (Cases only) | SW | 2.5% | 0.26 | [36] |
| Breast | (3) 1,434 | (Cases only) | NE | 3.4 (0.4–32.6) | 0.3 | [58] |
| Melanoma | (15) 1,889/(59) 12,801 | (Combined) | | 1.79 (1.02–3.17) | | [59] | | | DE | 2.01 (1.03–3.91) | | | | | GE | 1.42 (0.46–4.31) | | |
| Melanoma | (18) 2,619/(67) 17,481 | (Meta-analysis) | | 1.81 (1.07–3.05) | | [59] |
| Colorectal | (8) 818/(5) 760 | (Unselected) | SW | 1.49 (0.49–4.58) | 0.48 | [60] | (2) 174/(5) 760 | (Familial) | | 1.76 (0.34–9.13) | 0.50 | |
| Colorectal | 369 | (Cases only) | NE | 4.2% HNPCC cases | | [61] |
| Colorectal | 4,194/10,010 | (Meta-analysis) | | 2.11 (1.41–3.16) | 0.0003 | [62] | 1,050/3,784 | (Familial) | | 2.80 (1.74–4.51) | <0.0001 | | 652/2,115 | (Sporadic) | | 1.45 (0.49–4.30) | 0.50 | |
| Colorectal | (0) 210/(0) 446 | (Cases/controls) | TUK | | | [16] |
| Esophagus | (8) 551/(9) 644 | (Cases/controls) | NE | 1.04 (0.35–3.06) | 0.94 | [63] |
| Head & Neck | (0) 91 | (Case only) | GE | | | [64] |
| Ovary | (2) 268/(1) 821 | (Cases/controls) | RU | 6.17 (0.56–68.3) | 0.09 | [65] |
| Pancreas | (0) 270/(0) 683 | (Cases/controls) | CZ | | | [66] |
| Leukemia | (8) 973/(18) 1,620 | (Cases/controls) | UK | 0.74 (0.32–1.7) | | [67] |
| Lung | (0) 457 | (Cases only) | NE | | | [58] |
| Brain | (0) 79 | (Familial cases) | FR | | | [68] |
|
|
UK: United Kingdom, FI: Finland, NE: Netherlands, GE: Germany, RU: Russia, CA: Canada, SW: Sweden, US: United States, DE: Denmark, GE: Germany, MAL: Malaysia, AU: Australia, KO: Korea, IR: Ireland, SP: Spain, CHL: Chile, FR: France, PL: Poland, TUK: Turkey, and CZ: Czech.
|